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miRNA- and cytokine-associated extracellular vesicles mediate squamous cell
carcinomas
Joseph P. Flemminga*, Brianna L. Hilla*, Mohammed W. Haquea*, Jessica Raada, Claudine S. Bonderb,
Larry A. Harshynec, Ulrich Rodecka, Adam Luginbuhld, James K. Wahl IIIe, Kenneth Y. Tsaif, Peter J. Wermutha,
Andrew M. Overmillera† and Mỹ G. Mahoneya
a
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA; bCentre for Cancer Biology,
University of South Australia and SA Pathology, Adelaide, SA, Australia; cDepartment of Medical Oncology, Thomas Jefferson University,
Philadelphia, PA, USA; dDepartment of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, PA, USA;
e
Department of Oral Biology, University of Nebraska Medical Center, Lincoln, NE, USA; fDepartment of Tumor Biology, Moffitt Cancer Center,
Tampa, FL, USA

ABSTRACT

KEYWORDS

Exosomes, or small extracellular vesicles (sEVs), serve as intercellular messengers with key roles in
normal and pathological processes. Our previous work had demonstrated that Dsg2 expression in
squamous cell carcinoma (SCC) cells enhanced both sEV secretion and loading of pro-mitogenic
cargo. In this study, using wild-type Dsg2 and a mutant form that is unable to be palmitoylated
(Dsg2cacs), we investigated the mechanism by which Dsg2 modulates SCC tumour development
and progression through sEVs. We demonstrate that palmitoylation was required for Dsg2 to
regulate sub-cellular localisation of lipid raft and endosomal proteins necessary for sEV biogen
esis. Pharmacological inhibition of the endosomal pathway abrogated Dsg2-mediated sEV
release. In murine xenograft models, Dsg2-expressing cells generated larger xenograft tumours
as compared to cells expressing GFP or Dsg2cacs. Co-treatment with sEVs derived from Dsg2over-expressing cells increased xenograft size. Cytokine profiling revealed, Dsg2 enhanced both
soluble and sEV-associated IL-8 and miRNA profiling revealed, Dsg2 down-regulated both cellular
and sEV-loaded miR-146a. miR-146a targets IRAK1, a serine-threonine kinase involved in IL-8
signalling. Treatment with a miR-146a inhibitor up-regulated both IRAK1 and IL-8 expression.
RNAseq analysis of HNSCC tumours revealed a correlation between Dsg2 and IL-8. Finally,
elevated IL-8 plasma levels were detected in a subset of HNSCC patients who did not respond
to immune checkpoint therapy, suggesting that these patients may benefit from prior anti-IL-8
treatment. In summary, these results suggest that intercellular communication through cell-cell
adhesion, cytokine release and secretion of EVs are coordinated, and critical for tumour growth
and development, and may serve as potential prognostic markers to inform treatment options.

Desmoglein; extracellular
vesicles; interleukin;
palmitoylation; carcinomas;
xenograft

Abbreviations: Basal cell carcinomas, BCC; Betacellulin, BTC; 2-bromopalmitate, 2-Bromo; Cluster
of differentiation, CD; Cytochrome c oxidase IV, COX IV; Desmoglein 2, Dsg2; Early endosome
antigen 1, EEA1; Epidermal growth factor receptor substrate 15, EPS15; Extracellular vesicle, EV;
Flotillin 1, Flot1; Glyceraldehyde-3-phosphate dehydrogenase, GAPH; Green fluorescent protein,
GFP; Head and neck squamous cell carcinoma, HNSCC; Interleukin-1 receptor-associated kinase 1,
IRAK1; Interleukin 8, IL-8; Large EV, lEV; MicroRNA, miR; Palmitoylacyltransferase, PAT; Ras-related
protein 7 Rab7; Small EV, sEV; Squamous cell carcinoma, SCC; Tissue inhibitor of metalloprotei
nases, TIMP; Tumour microenvironment, TME
KEYWORDS Desmoglein; extracellular vesicles; interleukin; palmitoylation; carcinomas; xenograft

Introduction
The coordinated response of cell-to-cell and cell-tomicroenvironment communication plays a critical
role in biological processes including embryogenesis,
maintenance of homoeostasis and pathological condi
tions [1]. During tumorigenesis, autocrine as well as

paracrine signals from cancer cells enable growth,
angiogenesis and metastasis. The three major forms
of intercellular communication include direct cell-cell
contacts, secretion of soluble regulatory factors such as
cytokines, and the recently discovered release of spe
cialised membranous extracellular vesicles (EVs) [2].
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However, whether these modes of communication are
interconnected is far more complex than previously
understood. It is well established that cytokines, EVs
and cell surface presentation of adhesion proteins play
a role in tumorigenesis but how they modulate, in
context of each other, is not known.
Desmoglein 2 (Dsg2) is a transmembrane compo
nent of desmosomal cell-cell adhesion structures,
which provides tensile strength by linking the trans
membrane adhesive components to the intermediate
cytoskeletal keratin filaments [3]. Mutations in the
human Dsg2 gene underlie some arrhythmogenic
right ventricular cardiomyopathies [4]. Interestingly,
in human pluripotent stem cells, Dsg2 is critical for
self-renewal, embryonic body and teratoma formation,
and mediates the epithelial-to-mesenchymal transition
through a β-catenin/Slug pathway [5]. In mice, ablation
of the Dsg2 gene results in loss of the trophectoderm
layer in blastocysts and triggers embryonic lethality
without affecting cell-cell adhesion [6]. Dsg2 is highly
expressed in malignant epithelial cell lines and in the
two most common skin cancers, basal cell carcinomas
(BCCs) and SCCs [7,8]. Furthermore, Dsg2 promotes
vasculogenic mimicry to increase tumour blood supply
and is associated with poor prognosis in malignant
melanoma [9,10]. Over-expression of Dsg2 also occurs
in prostate and colon cancers, suggesting a role for
Dsg2 in oncogenesis in a variety of epithelial-derived
tumours [11]. In vitro, Dsg2 can activate multiple
growth and survival signalling pathways, and enhances
epithelial cell proliferation and migration [12,13].
Knockdown of Dsg2 in colonic epithelial carcinoma
cells decreases proliferation and suppresses xenograft
tumour growth in mice [14]. We have demonstrated
that forced expression of Dsg2 in the epidermis of
transgenic mice promotes epidermal hyperplasia and
increases susceptibility to tumour development [12].
Furthermore, these transgenic mice provide several
lines of evidence supporting a paracrine signalling
role of Dsg2 including enhanced proliferation in a
different cell compartment and activation of hedgehog
signalling in the dermis [8,12]. Through Stat3, Dsg2
up-regulates Gli1 and Ptch1, target genes of the Hh
signalling pathway and compound Dsg2/Ptc1+/lacZ
mice have accelerated development of BCCs and
SCCs and tumorigenesis in response to chemical carci
nogens [8,15].
We recently demonstrated that Dsg2 regulates sEV
biogenesis, increases their mitogenic content including
EGFR and c-Src, and enhances their pro-proliferative
effects on dermal fibroblasts [13]. EVs are secreted by
virtually every cell type and are stratified by their size

or their mechanism of biogenesis [16]. They are a
diverse population, including sEVs such as exosomes
(30–150 nm), and large EVs (lEVs) such as microvesi
cles (0.1–1 µm), apoptotic bodies (1–5 µm) and onco
somes (1–10 µm). These vesicles may contain various
RNA species, DNA, proteins and lipid cargo that can
be taken up by distant cell types and alter the pheno
type of these recipients [17]. sEVs are becoming
increasingly associated as impactful contributors to
intercellular signalling systems that likely play a crucial
role in tumorigenesis and metastasis via alteration of
the tumour microenvironment (TME) [18]. One of the
critical factors transported via sEVs that modulate
these processes are microRNA (miRNAs). miRNAs
are post-transcriptional regulators of protein transla
tion that alter both pro- and anti-oncogenic pathways
[19]. Understanding the complement of miRNA pre
sent in tumour-derived EVs, and their downstream
targets, is crucial for the progression of our under
standing of the TME and the development of novel
therapeutic options.
In this study, we show that Dsg2 modulates sEV
biogenesis in a palmitoylation-dependent manner by
altering the sub-cellular localisation of proteins asso
ciated with membrane rafts and the endosomal proces
sing pathway. The pro-oncogenic effect and
tumorigenicity of Dsg2 correlate with sEV levels.
Furthermore, we show that sEVs released in response
to Dsg2 are enriched in cytokines, most notably the
pro-chemotactic and -angiogenic factors, IL-8.
Interestingly, in both cells and sEVs, RNAseq detected
down-regulation of miR-146a in response to Dsg2,
which has been shown to target IRAK1, possibly
explaining this increase in IL-8 in SCC cells in response
to Dsg2.

Materials and methods
Antibodies
Antibodies used for Western blotting: 6D8 Dsg2 (1:100);
10D2 Dsg2 (1:100); from Invitrogen (Carlsbad, CA),
cluster of differentiation 63 (CD63; 1:1000), interleukin
8 (IL-8; 1:500); from Cell Signalling Technology
(Danvers, MA), early endosome antigen 1 (EEA1;
1:1000), epidermal growth factor receptor substrate 15
(EPS15; 1:1000), flotillin 1 (Flot1; 1:1000), green fluores
cent protein (GFP; 1:1000), cytochrome c oxidase IV
(COX IV; 1:1000), glyceraldehyde-3-phosphate dehydro
genase, (GAPDH; 1:3000); from Santa Cruz
Biotechnology (Santa Cruz, CA), CD9 (1:500); from LICOR Biosciences (Lincoln, NE), goat anti-rabbit or
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-mouse Odyssey 800 (1:15,000) and 680 (1:20,000).
Antibodies used for immunofluorescence: 10D2 Dsg2
(1:2); Flot1 (1:100); EEA1 (1:200); EPS15 (1:200); Rab7
(1:250, Cell Signalling Technology); from Molecular
Probes (Eugene, OR), goat anti-rabbit and -mouse
Alexa Fluor 488 and 594 (1:400).
Generation of Dsg2 mutant cell lines
The stop codon of the human Dsg2 cDNA was
removed and sub-cloned into vector pEGFP-N1
(Clontech, Mountain View, CA) upstream of the GFP
as previously described in detail [13,20,21]. For
Dsg2cacs cDNA, two cysteine point mutations were
generated using the QuikChange site directed muta
genesis kit (Stratagene, San Diego, CA) [20]. The
mutated cDNAs were then sub-cloned into the retro
viral expression vector LZRS-ms-neo and transfected
into Phoenix cells to package retroviral particles.
Human A431 (epidermoid skin carcinoma) or UMSCC1 (oral SCC) cells were selected in medium con
taining G418 (500 µg/mL) after retroviral transduction.
While these SCC cell lines express some endogenous
levels of Dsg2, forced expression of higher levels of
wild-type or mutant Dsg2 was possible using transfec
tion of retrovirus expression constructs.
Cell culture
Cell lines were plated at 3 × 106 cells per 100 mm dish
in complete DMEM containing 10% FBS (Peak Serum,
Fort Collins, CO) and P/S (Thermo Fisher, Waltham,
MA) as previously described [13]. At 80% confluency,
cells were cultivated in serum free media for 48 h. The
conditioned media was then collected for EV purifica
tion.
Cells were
trypsinised and
counted
(Haemocytometer, Thermo Fisher). For drug treat
ment, cells were treated with 2-Bromopalmitate (50
µM, Sigma, St. Louis, MO), GW4869 (10 µM,
Cayman Chemical, Ann Arbour) or Bafilomycin A1
(0.02 µM, Cayman Chemical) for 48 h in serum free
medium and conditioned medium was collected for EV
isolation and analysis.
Immunofluorescence
Cells grown on glass slides were washed in cold PBS,
fixed in 4% PFA (Electron Microscopy Sciences,
Hatfield, PA) for 15 min at room temperature (RT)
and then permeabilised with 1% TX-100 in PBS for 5
min at RT. Cells were blocked in 5% normal goat
serum (NGS), 0.1 M glycine, 0.02% TX-100 in PBS
for 1 h at RT and incubated in 1° Ab in blocking buffer
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at 4°C overnight. Cells were washed in PBS and incu
bated in 2° Ab in blocking buffer for 1 h at RT.
Following secondary incubation, cells were washed
again in PBS and then incubated with DAPI (1:1000,
Sigma) in PBS for 5 min. Cells were washed in PBS and
mounted in Fluoromount-G (Southern Biotech,
Birmingham, AL), and images were captured by A1R
+ Nikon confocal microscopy (Melville, NY).

Western blotting analysis
For Western blotting, cells were washed in ice-cold PBS
and lysed with lysis buffer (10 mM Tris pH 7.5, 150 mM
NaCl, 0.5 mM EDTA, 0.1% SDS, 1% deoxycholate, 1%
TX-100) supplemented with PMSF (1 µM), protease
inhibitor cocktail (Thermo Fisher) and phosphatase inhi
bitor cocktail (Thermo Fisher) and heated to 95°C for 10
min in Laemmli buffer. Proteins were resolved over SDSPAGE (Bio-Rad Labs, Hercules, CA) and transferred to
nitrocellulose membrane. Non-specific sites were
blocked with blocking buffer (5% BSA in TBS) and
incubated in primary antibodies in blocking buffer (5%
BSA in TBST (TBS + 1% TX-100)) overnight at 4°C.
Membranes were washed in TBST and incubated with
secondary antibody in blocking buffer for 1 h. Infrared
bands were visualised by LI-COR Odyssey imaging sys
tem (LI-COR Biosciences, Lincoln, NE).

Extracellular vesicle purification
EV purification was performed using sequential ultra
centrifugation protocol [22]. Conditioned medium was
collected and subjected to serial centrifugation at 300 ×
g (10 min), 16,000 × g (30 min), and then 120,000 × g
(70 min; Ti45 rotor). The supernatant was aspirated
and the sEV pellet washed 1× with ice-cold PBS, resuspended in PBS and stored in −20°C. For iodixanol
purification, the 120,000 × g pellet containing sEVs and
co-contaminates was added to a 40% iodixanol solu
tion, which was used as the bottom fraction of a 40%/
30%/5% density gradient. Samples were centrifuged at
120,000 × g (Sorvall TH 641) O/N and 1 mL fractions
were collected from the top for analysis.

Trypsin digestion
sEVs were incubated at 37°C for 20 min with 0.04% trypsin
(Corning, Corning, NY) in a final volume of 12 µL. The
reaction was stopped by heat inactivation in Laemmli
buffer and samples were prepared for Western blotting.
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Nanoparticle tracking analysis

Murine blood plasma EV

EVs were analysed using the NanoSight NS300 (Malvern
Instrument, Westborough, MA) for size, shape and con
centration. NanoSight employs laser illumination to pro
voke light scattering and video capture of Brownian
motion to determine the size distribution and concentra
tion of particles in solution. EVs (diluted 1:250; ~107–109
particles/mL) were injected with a syringe pump (infuse
= 20, Malvern Instrument) and recorded (3 × 30-second
captures) to determine the mean size and concentration
of nanoparticles in each sample.

Mice were sacrificed and blood collected by cardiac punc
ture with a 1 mL syringe coated with 0.5 M EDTA. Blood
was then centrifuged at 2000 RPM for 20 min and plasma
was further centrifuged at maximum speed for 10 min.
EVs were purified using IZON Science LTD’s (Medford,
MA) size exclusion chromatography columns according
to the manufacturer’s protocol. The purified samples
were collected in five 200 µL fractions and analysed
using nanoparticle tracking analysis.
RNAseq

Transfection with miR-146a mimic and inhibitor
SCC A431 cells were seeded into six well plates at 2 ×
105 cells per well in DMEM containing 10% FBS and
cultured until 80% confluent. Cells were then cultivated
in serum free media for 12 h. MISSION negative con
trol miRNA (#HMC0002; Sigma-Aldrich), miR-146a5p mimic (#HMI0228; Sigma-Aldrich) or miR-146a-5p
inhibitor (#HSTUD0228; Sigma-Aldrich) were trans
fected into six wells for each cell line using
Lipofectamine 2000 (Thermo Fisher) according to the
manufacturer protocol. After 24 h, media was removed
from cultures and cells were washed with ice-cold PBS.
Triplicate wells of each treatment condition were lysed
in either Trizol for total RNA isolation or RIPA buffer
for cellular protein isolation and stored at −80°C for
further analysis.

Tumour xenograft
A431 or UM-SCC1 cells over-expressing GFP, Dsg2/
GFP or Dsg2cacs/GFP were established as described
previously [20]. Cells were trypsinised and re-sus
pended in DMEM (1 × 107 cells/mL) and injected
(100 µL) subcutaneously into the flanks of Balb/c
SCID mice (8–9 weeks of age). For sEV treatments,
20 µg of sEVs were injected at the time of tumour
implantation. Tumour length and width were mea
sured by caliper on a twice-weekly schedule beginning
7 days post-injection. Mice were also weighed to moni
tor general health. Experiments were to be terminated
at 28 days post-injection, except where excessive
tumour burden and decline in animal health necessi
tated termination at earlier time points. Animals were
sacrificed, and the tumour tissue was collected and
fixed in OCT or formalin for histology or immunohis
tochemistry. Note: all experiments conformed to the
Thomas Jefferson University IACUC protocols and
approval.

For miRNAseq, total RNA was harvested from A431
and A431-Dsg2/GFP cells and sEVs using the
miRNeasy Kit according to manufacturer’s instruction
(Qiagen, Germantown, MD). RNA quality (RIN) deter
mination and sequencing was performed by Avera
Health (Sioux Falls, SD). Reads were aligned to the
Genome Reference Consortium Human Build 37
(GRCh37), and the expression values were calculated
and analysed by Partek Genomics Suite (http://www.
partek.com). miRNAs with expression of RPKM ≥ 1
were considered for further analysis. Analysis of var
iance (ANOVA) was performed between all cell lines.
Heatmaps were created using Morpheus, https://soft
ware.broadinstitute.org/morpheus.
For gene expression in HNSCC tumour tissues, total
RNA was isolated from HNSCC tumour tissues using
RNeasy kits (Qiagen) and libraries were prepared using
TruSeq Stranded Total RNA kit (Illumina, San Diego,
CA) following manufacturer’s instructions. The final
libraries were sequenced on NextSeq 500 using 75bp
paired-end chemistry. Sequencing reads were aligned
with the reference genome of Homo sapiens Ensembl
Version GRCh38 and using information from the gene
transfer format (.gtf) annotation from GENCODE ver
sion GRCh38.p12 using RSEM [23]. Using RSEM’s cal
culate-expression function, total read counts and
normalised transcripts per million (TPM) were obtained.
Batch effects or sample heterogeneity was tested before
differential expression, using iSeqQC [24]. The DESeq2
package [25] in R/Bioconductor was used to analyse
differential gene expression. Scatter plot analysis was
used to assess the correlation of IL-8 and Dsg2 expres
sion, and R2 value provided to measure goodness-of-fit.
Real-time PCR
For qPCR, total RNA was collected from cells and sEVs
with the miRNeasy RNA Isolation Kit-Cell & Plant
(Exiqon,
VedBaek,
Denmark)
according
to
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manufacturer’s protocol. cDNA construction of total
RNA, including mature miRNAs, was performed with
the Universal cDNA Synthesis Kit II (Exiqon) accord
ing to manufacturer’s suggestion employing 10 ng of
cellular or EV RNA. qPCR was performed with
ExiLENT SYBR Green Master Mix (Exiqon) on the
ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA). For mRNAs:
IL-8 forward (5ʹ-GTG CAG TTT TGC CAA GGA
GT-3ʹ); IL-8 reverse (5ʹ-TTA TGA ATT CTC AGC
CCT CTT CAA AAA CTT CTC-3ʹ); IRAK1 forward
(5ʹ-TCA-GCT-TTG-GGG-TGG-TAG-TG-3ʹ); IRAK1
reverse (5ʹ-TAG-ATC-TGC-ATG-GCG-ATG-GG-3ʹ);
GAPDH forward (5ʹ-GGT GTG AAC CAT GAG
AAG TAT G-3ʹ); GAPDH reverse (5ʹ-GAG TCC TTC
CAC GAT ACC AAA G-3ʹ).
Cytokine antibody array
A431-GFP and -Dsg2/GFP cells were grown to con
fluency in 10 cm2 tissue culture dishes and then incubated
in serum-free medium for 48 h. Large and sEVs were
isolated from conditioned medium by sequential ultra
centrifugation and used to analyse a panel of 120 cyto
kines and chemokines (C-series Human Cytokine
Antibody Array C1000, AAH-CYT-1000-2; Raybiotech,
Norcross, GA) according to manufacturer’s protocol. The
quantification of dot intensity was performed in ImageJ
following background subtraction, and the raw data nor
malised to the array-specific positive control dots.
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Statistics
Results are mean ± SEM of at least three independent
experiments performed in triplicates. Two-tailed
Student’s t test was performed where needed. A
mixed model analysis was carried out using Prism
and either Tukey’s post hoc or Dunnett’s post hoc
tests where appropriate for repeated measures
ANOVA. P ≤ 0.05*; P ≤ 0.01**; P ≤ 0.001***.

Results
Characterisation of EVs
To study EVs, we adopted the standard isolation pro
tocol using sequential ultracentrifugation to remove
live cells and apoptotic bodies and to purify lEVs and
sEVs from A431 SCC cells (Figure 1(a)). EVs were
characterised by nanoparticle tracking analysis (NTA)
showing significantly overlapping sized particles in
both lEV and sEV preparations (Figure 1(b)).
Focusing on sEVs, electron micrographs revealed intact
vesicles from approximately 30 nm (left panel) to 100
nm (right panel) in diameter (Figure 1(c)). Western
blotting analysis confirmed the enrichment of the tet
raspanins CD63 and CD9 and the lipid raft protein
Flot1 in sEVs as compared to total cell lysates (Figure
1(d)) [21]. The mitochondrial protein COX IV was
completely absent from sEVs indicating an absence of
cellular contaminants. These results confirmed pre
vious findings that sequential ultracentrifugation is a
viable method to isolate sEVs from SCC cells [21,26]

HNSCC patients’ plasma IL-8
Blood samples were collected from patients with
HNSCCs enrolled in a window of opportunity trial of
Nivolumab and Tadalafil (NCT03238365) at Thomas
Jefferson University Hospital approved by the Thomas
Jefferson University Institutional Review Board. Blood
was collected in EDTA collection tubes at baseline and
surgery. Plasma was isolated following centrifugation at
300 × g for 20 min and was stored at −80°C. MILLIPLEX
MAP Human Cytokine/Chemokine Magnetic Bead
Panels (Millipore) were used to identify cytokines pre
sent in plasma collected from HNSCC patients. Samples
were analysed in triplicate by a FlexMAP 3D (Luminex)
and standard curves were generated for each cytokine
and median fluorescent intensities were transformed
into concentrations by five-point, non-linear regression.
Treatment effects were assessed by a pathologist.
Patients whose tumours exhibited > 20% pathologic
treatment effect at the primary site were deemed respon
ders (N = 10) and those with 20% > were labelled nonresponders (N = 18).

Palmitoylation of Dsg2 modulates sEV release in
SCC cells
Palmitoylation is a covalent attachment of the 16Cfatty acid, palmitate, to cysteine residues through thioe
ster linkage, important for proper protein localisation,
association with cellular membranes and lipid rafts,
protein trafficking and desmosome assembly [20,27–
30]. Disruption of palmitoylation has been implicated
in several disease states including cancer and treat
ments that target palmitoylated proteins or palmitoyla
cyltransferases (PATs) have the potential therapeutic
benefits [31]. We previously demonstrated that Dsg2
modulates EV release [21] and that palmitoylation of
Dsg2 is critical for desmosome assembly, protein turn
over and cell-cell adhesion [20]. However, whether
palmitoylation of Dsg2 is necessary for EV release is
unknown. Here we generated the cell lines stably
expressing GFP and Dsg2/GFP by retroviral infection
as previously described in detail [20] and confirmed
that up-regulation of Dsg2 in SCC cells enhanced sEV

6

J. P. FLEMMING ET AL.

Figure 1. Characterisation of EVs by sequential ultracentrifugation. (A) Schematic diagram of the serial centrifugation steps used to
isolate large and sEVs. (B) Dynamic light scattering measurement by nanoparticle tracking analysis (NTA) of EVs isolated from A431
SCC cells illustrating the concentration and size of particles present. (C) SEVs were loaded on a formvar carbon-coated EM mesh grid
and imaged on a transmission electron microscope showing vesicles ranging in size from approximately 30 nm (left) to 100 nm
(right). Scale bar, 100 µm. (D) Proteins from sEVs and total cell lysates (TLC) of A431 cells were resolved over SDS-PAGE and
immunoblotted for the tetraspanin markers (CD63 and CD9), lipid raft-associated protein (Flot1), mitochondrial protein (COXIV) and
GAPDH for equal loading.

release (Figure 2(e)). The effect of Dsg2 was abrogated
when cells were treated with 50 µM 2-bromopalmitate,
an irreversible inhibitor of PATs, which works through
covalent attachment to the catalytic cysteine residue
within the active site, thereby blocking the function of
all cellular PATs (Figure 2(a)). These results suggest
that protein palmitoylation plays a role in regulating

sEV release. However, we could not rule out off-target
effects on the other proteins critical for sEV biogenesis.
We recently identified the two cysteine residues
(C635 and C637) in the juxtamembrane (intracellular
anchor) domain of Dsg2 that, when mutated to alanine
and serine (C635A/C637S; cacs), respectively, abrogates
palmitoylation of Dsg2 [20]. Stable A431 SCC cell lines
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Figure 2. Loss of Dsg2 palmitoylation reduces EV release. (A) A431 SCC cells stably expressing GFP or Dsg2/GFP were treated with
the vehicle control (DMSO) or 2-bromopalmitate (2-Bromo) (50 uM). After 18 h, conditioned medium was collected and sEVs
isolated and counted by NTA. Values presented as percent control. GFP, 100 ± 7.9; GFP + 2-Bromo, 96.6 ± 8.6; Dsg2/GFP, 338.1 ±
123.7; Dsg2/GFP + 2-Bromo, 152.1 ± 10.7. N = 3. *P ≤ 0.05. (B) Schematic diagram showing the GFP, Dsg2/GFP and Dsg2cacs/GFP
fusion constructs. Dsg2cacs/GFP contains the mutations C635A and C637S and was previously described to eliminate Dsg2’s
palmitoylation [20]. (C) A431 SCC cells stably expressing GFP, Dsg2/GFP or Dsg2cacs/GFP as a palmitoylation deficient control. Cells
were lysed and proteins resolved by SDS-PAGE and immunoblotted with antibodies against Dsg2 or GFP (endogenous Dsg2: lower
160 kD band; exogenous Dsg2/GFP or Dsg2cacs/GFP upper band: 190 kD). GAPDH for equal loading. (D) Immunofluorescence of
A431-GFP, -Dsg2/GFP or -Dsg2cacs/GFP using antibodies against Dsg2 and GFP and imaged by confocal microscopy. Scale bar, 50
µm. (E) sEV production from A431 cells stably expressing GFP, Dsg2/GFP or Dsg2cacs/GFP. Values presented as percent control. GFP,
100 ± 14.7; Dsg2/GFP, 190.5 ± 16.0; Dsg2cacs/GFP, 94.9 ± 29.7. N = 17. *P ≤ 0.05; **P ≤ 0.01. (F) EVs isolated by ultracentrifugation
were separated over iodixanol gradient and fractions collected and processed for Western blotting.

were generated over-expressing constructs of Dsg2
fused to monomeric enhanced GFP, Dsg2/GFP or
Dsg2cacs/GFP (Figure 2(b)). Western blotting of total
cell lysates showed the 160 kD endogenous Dsg2 pro
tein in A431 cells expressing GFP (Figure 2(c)). An

additional 190 kD band representing the Dsg2/GFP
or Dsg2cacs/GFP fusion proteins was observed in
those respective cells. Immunostaining for GFP con
firmed cytoplasmic staining for GFP and cell-cell bor
der staining for Dsg2/GFP and, to a lesser extent,
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Dsg2cacs/GFP (upper panels; Figure 2(d)). Anti-Dsg2
antibodies detected the endogenous Dsg2 in the GFP
cells which was dramatically enhanced in Dsg2/GFP
and Dsg2cacs/GFP cells (lower panels; Figure 2(d)).
As anticipated, the Dsg2cacs/GFP cells displayed less
distinct cell-cell border signals. The cytoplasmic GFP
signal observed in the Dsg2/GFP or Dsg2cacs/GFP cells
may result from cleavage of the GFP from Dsg2 or
Dsg2cacs as the lower panels clearly show more Dsg2
and Dsg2cacs protein.
sEVs were collected from conditioned media of cells
expressing GFP, Dsg2/GFP and Dsg2cacs/GFP and ana
lysed by NTA showing the effect of Dsg2 on EV biogen
esis was dramatically abrogated in cells expressing
palmitoylation-deficient Dsg2cacs (Figure 2(e)). Willms
et al. reported two different sub-populations of small EVs,
low- and high-density, with distinct molecular composi
tion and biological properties [32]. Here, by bottomloading, density gradient separation we observed CD63
(sEV marker) predominantly in the low-density, 5%
iodixanol fractions 3 and 4 (top and middle panels;
Figure 2(f)). Loss of Dsg2 palmitoylation dramatically
shifted CD63 into the high-density 30–40% iodixanol
fractions 7–9 (lower panel; Figure 2(f)). These results
suggest that palmitoylation of Dsg2 is essential for proper
cargo loading into low-density sEVs and disturbing pal
mitoylation induces more high-density sEVs, while still
reducing sEV biogenesis as a whole.
Dsg2 modulates sEV biogenesis through the
endocytic pathway
To further elucidate the mechanism by which Dsg2
promotes sEV release, we examined the effect of Dsg2
on the endocytic pathway. We first examined the
effects of Dsg2 on Flot1, EPS15, EEA1 or Rab7. Flot1
is an integral membrane protein that forms discrete
planar micro-domains in lipid rafts and is involved in
endocytosis, signal transduction and the regulation of
cytoskeletal elements [33]. Importantly, Flot1 localises
to the plasma membrane and has been detected in early
endosomes and EVs. Here, shown by immunofluores
cence (Figure 3(a)) and immunoblotting (Figure 3(b)),
Dsg2 increased not only the expression of Flot1 as
shown in the graphs depicting quantitation of immu
noblot band intensity, but also promoted membrane
association. As previously mentioned, palmitoylation is
important for proper protein localisation and associa
tion with cellular membranes and lipid rafts. As such,
the loss of Dsg2 palmitoylation reduced the effect on
Flot1 in Dsg2cacs/GFP expressing cells (Figure 3(a,b))
Similar results were observed with EPS15, a scaffolding
adaptor protein associated with clathrin-coated pits,

responsible for endocytosis of cargo from outside of
the cell (Figure 3(a,b)). The effect of Dsg2 on EEA1, an
early endosomal protein acting as a ligand for Rab5
binding to endocytic vesicles or Rab7, a late endosomal
protein, was less pronounced (Figure 3(a,b)). It is
important to appreciate the difference in Western blot
ting and immunofluorescence when interpreting this
data. Immunofluorescence may have certain biases
towards cell compartments such as the plasma mem
brane, while quantitation of Western blotting bands
shows the total cellular levels. For this reason, the
differential production of the endocytic markers is
less apparent in the Western blot images in comparison
to the immunofluorescence..
To confirm that the endosomal pathway is involved
in Dsg2-mediated sEV release, A431-GFP and A431Dsg2/GFP cells were treated with the drug inhibitors
GW4869 and Bafilomycin A1 (BafA1). sEVs were iso
lated and counted by NTA. GW4869 is a neutral sphin
gomyelinase inhibitor that blocks ceramide-mediated
inward budding of multi-vesicular bodies (MVBs) and
the fusion of MVBs to the plasma membrane to release
sEVs. Here, GW4869 reduced sEV release (Figure 3
(c)). BafA1, on the other hand, inhibits vacuolar-type
proton ATPase (V-ATPase) preventing the acidifica
tion and fusion of the MVBs to the lysosomes and
drives sEV release [34]. Treatment with BafA1
increased sEV release (Figure 3(c)). The effect was
more dramatic with A431-Dsg2/GFP, as compared to
A431-GFP cells. The results thus far suggest that Dsg2
modulates sEV release through membrane invagination
and the endocytic pathway.
sEVs enhance SCC tumour development
To assess the effect of sEVs in xenograft tumour devel
opment, immunocompromised mice were injected sub
cutaneously with A431 cells over-expressing GFP,
Dsg2/GFP or Dsg2cacs/GFP (Figure 4(a)). Over the
course of 3–4 weeks, the Dsg2/GFP expressing cells
developed significantly larger tumours than their GFP
or Dsg2cacs/GFP expressing counterparts. Similar
results were obtained using the head and neck SCC
UM-SCC1 cells (Figure 4(b)). These findings suggest
that Dsg2 enhanced tumour development in both cuta
neous and head and neck SCCs. To rule out loss of
Dsg2 expression in the non-palmitoylated Dsg2cacs/
GFP cells, xenograft tissues were immunostained for
GFP. We observed strong GFP signals in all xenografts
demonstrating that the cells could maintain expression
of the recombinant GFP or Dsg2 constructs through
out the duration of the experiment. Cytoplasmic stain
ing was observed with A431-GFP xenografts while the
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Figure 3. Dsg2 alters early endocytic pathways and endosomal trafficking. (A) A431 cells expressing GFP, Dsg2/GFP and Dsg2cacs/
GFP were seeded, immunostained for Dsg2, Flot1, EPS15, EEA1 and Rab7 and then imaged by confocal microscopy. Note the subcellular localisation of Flot1, EPS15 and to some less extent EEA1 in the A431-Dsg2/GFP cells, which are reduced with the abrogation
of Dsg2 function by the cacs mutation (A431-Dsg2cacs/GFP). Scale bar, 20 µm. *P ≤ 0.05. (B) Lysates of A431 cells expressing GFP,
Dsg2/GFP or Dsg2cacs/GFP were resolved over SDS-PAGE and immunoblotted for Dsg2, endocytic pathway proteins (Flot1, EPS15,
EEA1) and GAPDH. Western blot was quantified using ImageStudio and signals were normalised to the GFP cell line. N = 3. Flot1
(GFP, 100 ± 0.0; Dsg2/GFP, 148.9 ± 14.5; Dsg2cacs/GFP, 100.6 ± 11.0); EPS15 (GFP, 100 ± 0; Dsg2/GFP, 146.1 ± 12.5; Dsg2cacs/GFP,
108.2 ± 5.2); EEA1 (GFP, 100 ± 0; Dsg2/GFP, 142.3 ± 11.1; Dsg2cacs/GFP, 89.2 ± 17.1). (C) A431-GFP and A431-Dsg2/GFP cells were
treated with GW489 and bafilomycin A1 for 48 h. sEVs were isolated and quantitated. A431-GFP (control, 100 ± 5.3; GW4869, 86.6 ±
10.8; BafA1, 247.1 ± 17.1); A431-Dsg2/GFP (control, 279.4 ± 65.5; GW4869, 99.9 ± 54.3; BafA1, 960.1 ± 153.0). N = 3. *P ≤ 0.05, **P ≤
0.01.
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Figure 3. (continued)

A431-Dsg2/GFP xenografts showed distinct cell-cell
border staining (Figure 4(c)). Similar to the in vitro
results (Figure 2(c)), while the Dsg2cacs/GFP cells
expressed high levels of the mutated Dsg2, the staining
was less punctated at the cell border (Figure 4(c)).
These results confirm that the cells retained their abil
ity to express the transgene in vivo. Although we have
observed increased proliferation in response to Dsg2
over-expression in vitro, the exact parameters allowing
us to resolve the difference in growth rates between the

cell lines were experimentally determined at very low
cell densities (~5 × 103 cells). Considering that our in
vivo results are at densities ~3.5 orders of magnitude
higher than these in vitro observations, we sought to
explore other mechanisms to explain the difference in
tumour growth.
Next, to assess whether the increased tumour
volume correlates with sEV release, blood plasma was
isolated from the xenografted mice upon the comple
tion of experiments. sEVs were isolated by IZON qEV
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Figure 4. The pro-tumorigenic effect of Dsg2 is abrogated with loss of palmitoylation and rescued with EV treatment. (A)
Immunocompromised Balb/c SCID mice were subcutaneously injected with 1 × 106 of A431-GFP, -Dsg2/GFP or – Dsg2cacs/GFP
cells. Tumour growth was measured, and average tumour volumes were calculated to determine the tumorigenicity for each cell
line. N = 8, 13, 16, respectively. Tumour volume in mm3: Day 7 (GFP, 2.0 ± 1.4; Dsg2/GFP, 14.5 ± 4.8; Dsg2cacs/GFP, 2.2 ± 1.3); Day 9
(GFP, 7.5 ± 3.7; Dsg2/GFP, 96.3 ± 31.3; Dsg2cacs/GFP, 29.1 ± 9.4); Day 14 (GFP, 57.9 ± 19.0; Dsg2/GFP, 323.3 ± 45.3; Dsg2cacs/GFP,
104.4 ± 17.2); Day 17 (GFP, 81.3 ± 22.4; Dsg2/GFP, 596.2 ± 133.7; Dsg2cacs/GFP, 146.4 ± 25.8); Day 21 (GFP, 157.1 ± 39.8 Dsg2/GFP,
768.0 ± 162.5; Dsg2cacs/GFP, 279.5 ± 42.9). *, A431-Dsg2/GFP vs A431-GFP; Δ, A431-Dsg2/GFP vs A431-Dsg2cacs/GFP. (B) UM-SCC1
cells were used to establish lines over-expressing GFP, Dsg2/GFP or Dsg2cacs/GFP and injected subcutaneously in SCID mice to
establish tumour xenografts in the flanks as described above. Tumour volume was measured weekly. Tumour volume in mm3: Day 7
(GFP, 4.1 ± 2.6; Dsg2/GFP, 16.4 ± 5.6; Dsg2cacs/GFP, 21.1 ± 5.5); Day 10 (GFP, 17.0 ± 3.9; Dsg2/GFP, 70.8 ± 11.6; Dsg2cacs/GFP, 47.7
± 8.8); Day 14 (GFP, 56.8 ± 4.7; Dsg2/GFP, 227.4 ± 56.0; Dsg2cacs/GFP, 143.8 ± 34.9); Day 17 (GFP, 124.2 ± 25.0; Dsg2/GFP, 351.1 ±
53.6; Dsg2cacs/GFP, 224.1 ± 44.3); Day 19 (GFP, 147.1 ± 20.2; Dsg2/GFP, 429.1 ± 69.5; Dsg2cacs/GFP, 245.9 ± 43.9); Day 24 (GFP,
292.1 ± 56.0; Dsg2/GFP, 486.6 ± 59.0; Dsg2cacs/GFP, 410.6 ± 60.7). *, UM-SCC1-Dsg2/GFP vs UM-SCC1-GFP; Δ, UM-SCC1-Dsg2/GFP
vs UM-SCC1-Dsg2cacs/GFP. N = 9, 16, 15, respectively. (C) Immunofluorescence of tumour sections derived from A431-GFP, -Dsg2/
GFP and -Dsg2cacs/GFP xenografts in vivo showing sub-cellular localisation of Dsg2. Nuclei stained with DAPI (blue). Scale bar = 10
µm. (D) EVs were isolated by IZON size exclusion chromatography from blood plasma of mice in (A) and counted by NTA. Values
presented as percent control. GFP, 100 ± 24.5; Dsg2/GFP, 255.1 ± 47.3; Dsg2cacs/GFP, 144.8 ± 20.5. *P ≤ 0.05; **P ≤ 0.01. (E)
Immunocompromised Balb/c SCID mice were subcutaneously injected with 1 × 106 of A431-GFP, A431-Dsg2/GFP or A431-GFP along
with A431-Dsg2/GFP-derived sEVs. Tumour growth was measured, and average tumour volumes were calculated to determine the
tumorigenicity of each cell line N = 5, 4, 7, respectively. Tumour volume in mm3: Day 7 (GFP, 2.4 ± 2.2; GFP + sEV, 11.4 ± 7.1; Dsg2/
GFP, 11.4 ± 7.1); Day 10 (GFP, 6.4 ± 3.8; GFP + sEV, 11.4 ± 20.8; Dsg2/GFP, 69.4 ± 13.4); Day 14 (GFP, 19.1 ± 8.2; GFP+sEV, 40.3 ±
65.2; Dsg2/GFP, 303.8 ± 113.4); Day 17 (GFP, 96.2 ± 39.0; GFP+sEV, 181.7 ± 79.3; Dsg2/GFP, 558.0 ± 171.8); Day 21 (GFP, 109.9 ±
46.9; GFP+sEV, 377.5 ± 190.6; Dsg2/GFP, 683.1 ± 133.1); Day 24 (GFP152.7 ± 61.7; GFP+sEV, 516.0 ± 253.1; Dsg2/GFP, 891.2 ±
137.5); Day 26 (GFP, 165.0 ± 75.9; GFP + sEV, 608.2 ± 292.6; Dsg2/GFP, 1162.6 ± 201.5). *, A431-Dsg2/GFP vs A431-GFP; Δ, A431Dsg2/GFP vs A431-Dsg2cacs/GFP; *P ≤ 0.05; **P ≤ 0.01.
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column chromatography according to the manufac
turer’s instructions and sEVs counted by NTA.
Similar to the in vitro findings in Figure 2(e), larger
number of sEVs was detected in circulating plasma of
mice carrying A431-Dsg2/GFP xenografts as compared
to A431-GFP (Figure 4(d)). While the number of
plasma sEVs in A431-Dsg2cacs/GFP mice was signifi
cantly higher than those with A431-GFP, it was signif
icantly reduced compared to the A431-Dsg2/GFP
(Figure 4(d)). To further demonstrate that the increase
in tumour development is mediated through vesicles,
sEVs were isolated from A431-Dsg2/GFP cells and coinjected with the A431-GFP cells in xenografts. Despite
having been exposed to just a single dose of 20 µg
sEVs, we observed a marked and significant increase
in tumour size compared to the A431-GFP cells coinjected with a PBS volume control (Figure 4(e)). Thus
far, the results suggest that Dsg2 enhances SCC tumour
development possibly through sEV release and that a
single dose of sEVs enhances the tumorigenic potential
of the SCC cells.
Dsg2 enhances EV-bound cytokine release
Cytokines are small molecular weight soluble factors
with a wide range of biological functions and have been
shown to play a critical role in tumour cell growth and
progression, angiogenesis, and metastasis. To explore
the alteration of cytokine release in response to Dsg2
expression and to elucidate the mechanism by which
sEVs promote tumour development, we employed a
human secretome antibody array using conditioned
medium (contains all EVs), lEVs and sEVs isolated by
ultracentrifugation from A431-GFP and A431-Dsg2/
GFP cells (Figure 5(a)). Results were normalised to
the array-specific negative (black boxes) and positive
(blue boxes) control signal and plotted (Figure 5(b,c)).
In response to Dsg2, the secretion of eight cytokines
was up-regulated while two were down-regulated in the
conditioned medium (Figure 5(b) and Table 1). No
major changes in cytokines were observed in lEVs.
However, in sEVs 11 cytokines were enhanced in
response Dsg2 (Figure 5(c) and Table 2). EGFR as
well as the ligand betacellulin (BTC) were markedly
enriched in sEVs but not in the conditioned medium.
On the other hand, the tissue inhibitor metalloprotei
nases 1 and 2 (TIMP1 and 2), highly involved in most
cancers, were found at high levels in the control cells
and TIMP2 was slightly enriched in the conditioned
medium in response to Dsg2 (Figure 5(b,c)). However,
both TIMP1 and 2 were significantly reduced in the
sEV samples as compared to the conditioned medium
(Figure 5(b,c)). Interestingly IL-8, a potent angiogenic

and chemotactic factor known to play a role in tumour
development and immune recruitment [35], was
enriched in sEVs. These results suggest a mechanism
of active sorting into sEVs, which served as our reason
ing to pursue this further as a possible mechanism.
To further confirm that IL-8 was present specifically
in sEVs and not contaminant particles or protein
aggregates, A431-Dsg2/GFP sEVs from ultracentrifuga
tion were resolved over an iodixanol gradient to
remove aggregate contaminants (Figure 6(a)).
Proteins from the CD63 enriched fraction (*, Figure 6
(a)) were harvested and incubated with the cytokine
array to confirm the presence of IL-8. Recent evidence
supports the presence of several cytokines including IL8 on the surface of EVs, and therefore able to activate
its receptors on recipient cells [36]. Here, to determine
whether IL-8 was present on the surface of sEVs, iodix
anol purified samples from fraction 4 (*, Figure 6(a))
were treated with trypsin, which degraded the surface
IL-8 while maintaining EV integrity suggesting its loca
tion to be on the outside of the vesicles (Figure 6(c)).
This is as opposed to GAPDH level, which was largely
unchanged due to its localisation to the inside of sEVs.
Dsg2 regulates IL-8 by down-regulating miR-146a
miRNAs are small non-coding RNA molecules that are
emerging as important regulators of diverse biological
processes and miRNA-dependent regulation of the IL-8
gene has been reported in many pathological conditions
including inflammation and cancer [37–41]. In addition,
miR-146a modulates senescence and inflammation by
targeting IL-8 [42,43]. To investigate the role of Dsg2 in
the regulation of miRNAs, miRNA-sequencing (miRNASeq) on cellular and sEV-derived miRNAs from A431
and A431-Dsg2/GFP cells was performed. The results of
the RNA-Seq analysis showed that 93 total cellular
miRNAs were altered (50 up-regulated and 43 downregulated) in response to Dsg2 (Figure 7(a) and Table
3). In sEVs, 19 miRNAs changed in response to Dsg2
with 16 up-regulated and 3 down-regulated. Of those,
only 8 of the 19 were similar between the cells and
sEVs, suggesting that some miRNAs were selectively
and actively packaged into sEVs. Interestingly,
miR146a-5p (miR146a) was the most down-regulated
miRNA in response to Dsg2 at both the cellular level as
well as in sEVs (Figure 7(a)). The mechanism by which
Dsg2 modulates miRNAs remains to be determined.
While miR-146a does not directly target IL-8, it does
inhibit IRAK1 and its ability to activate transcription of
NFkB target genes such as IL-8, thereby regulating IL-8
expression [44,45]. To examine the direct effect of
miR-146a on IL-8 and IRAK1, A431 cells were treated
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Figure 5. Dsg2 enhances the release of the pro-inflammatory cytokine IL-8 through EVs. (A) Human cytokine antibody array C6 and
C7 were assayed with conditioned medium, large or sEVs harvested from A431-GFP and A431-Dsg2/GFP cells and processed
according to the manufacturer’s protocol. Blue boxes, positive controls; black boxes, negative controls; red boxes, IL-8 signals. [(B)
and (C)] Densitometry was performed on each cytokine by ImageJ software. Histogram bars represent the relative intensity value of
each cytokine altered in response to Dsg2 (blue: A431-GFP; red: A431-Dsg2/GFP) from conditioned medium (B) or sEVs (C). Data
were normalised to on-membrane positive control and depicted as relative abundance in samples ± SEM. N = 2.

with miR-146a mimic or inhibitor, with scrambled
miRNA as control. IL-8 (Figure 7(b)) and IRAK1
(Figure 7(c)) expression was analysed by qPCR. The
miR-146a mimic decreased both IRAK1 and IL-8
expression while the inhibitor increased their expres
sion levels suggesting that Dsg2 may modulate IL-8
expression through down-regulation of miR-146a.
Correlation between Dsg2 and IL-8 and
responsiveness to immune checkpoint therapy
IL-8 and Dsg2 have been shown up-regulated in HNSCCs
[21,46]. Here, we analysed the correlation between Dsg2
and IL-8 levels in 14 HNSCC tumour tissues using

RNAseq showing a moderate Pearson correlation coeffi
cient (R2 = 0.52; P = 0.0035) between Dsg2 and IL-8
expression (Figure 8(a)). To further establish the relevance
of our current findings in an in vivo setting, we assessed the
correlation of circulating blood levels of IL-8 and response
to immune checkpoint therapy. Blood plasma was col
lected from HNSCC patients (n = 28) prior to treatment
with the PD-1 inhibitor, Nivolumab and IL-8 level was
measured by ELISA. Subsequent to treatment, patients
were stratified according to clinical response to
Nivolumab (red = non-responder and blue = responder)
showing those who responded to the drug treatment had
significantly lower levels of IL-8 as compared to those that
did not show a positive response (Figure 8(b)). These
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Figure 5. (countiued)
Table 1. Changes in cytokines secreted by squamous carci
noma cells in response to Dsg2.
Conditioned medium
Array protein
IL-6
GM-CSF
ICAM-1
IGFBP-6
IL-8
PDGF-BB
TNFRI
TIMP2
GROa/b/g
CCL5

Class
Chemoattractant
Growth factor
Adhesion molecule
Growth factor
Chemoattractant
Growth factor
Cell surface receptor
Metalloproteinase inhibitor
Chemoattractant
Chemoattractant

Fold change
2.22
1.95
1.74
1.67
1.57
1.49
1.30
1.11
0.76
0.51

P value
4.2E-3
5.2E-3
3.6E-2
1.8E-2
3.3E-2
9.5E-3
1.5E-3
2.3E-2
1.2E-2
5.6E-3

results suggest that those with lower levels of circulating
IL-8 responded better to immune checkpoint therapy.

Discussion
Here we present evidence that the pro-oncogenic, stem
cell marker Dsg2 promotes SCC development and

Table 2. Changes in cytokines associated with small extracel
lular vesicles secreted by squamous carcinoma cells in response
to Dsg2.
Small extracellular vesicles
Array protein
I-TAC
IL-8
MIP-1B
ANGPT2
CCL28
BTC
EGFR
TRAIL (R4)
IGFBP-3
Dtk
ICAM-1

Class
Chemoattractant
Chemoattractant
Chemoattractant
Growth factor
Chemoattractant
Growth factor
Growth factor receptor
TRAIL-binding protein
Growth factor
Receptor tyrosine kinase
Adhesion molecule

Fold change
5.46
5.36
3.56
2.80
2.52
2.31
2.22
2.05
1.73
1.49
1.59

P value
4.3E-4
8.3E-3
9.6E-3
1.4E-2
1.1E-2
2.4E-2
2.2E-2
4.2E-2
1.3E-2
3.8E-2
4.4E-2

progression through down-regulation of miR-146a,
resulting in increased production of IL-8, packaged
and released in sEVs (Figure 9). These findings are
supported by clinical data showing that low plasma
levels of IL-8 correlate with HNSCC patients’ respon
siveness to immune checkpoint therapy.
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Figure 6. IL-8 is present on the surface of sEVs. (A) Conditioned medium derived from A431-Dsg2/GFP cells was used to isolate sEVs
by sequential ultracentrifugation and iodixanol separation. Fractions were collected from the top and immunoblotted for CD63. (B)
Fraction 4, enriched in CD63, was digested with trypsin (0.2%) and then subjected to Western blotting analysis for IL-8 and GAPDH.

During sEV biogenesis, proteins are internalised
through the plasma membrane into endocytic vesicles,
which merge to form early endosomes and then are
sorted for recycling, degradation or secretion [47]. The
role of post-translational modifications of membrane
proteins in this dynamic process is not fully under
stood. Palmitoylation is a reversible lipid modification
that influences protein conformation and stability, pro
tein-protein interaction and membrane trafficking.
Protein palmitoylation is regulated by palmitoyl acyl
transferases. Strong evidence supports a link between
protein palmitoylation and EV biogenesis and many of
these palmitoylated proteins are enriched in sEVs
including Dsg2 [48–50]. Here we demonstrate that
the palmitoylation state of Dsg2 is critical for traffick
ing of membrane raft proteins and early endosomal

proteins (Figure 3(a)) and thereby modulates sEV
release (Figure 2(d)). These results suggest that muta
tion at these cysteines affects the function of Dsg2 or
other proteins and pathways in modulating sEV
release. This study does not eliminate the likelihood
of other conserved cysteines across different effector
proteins that may also play a role in sEV biogenesis,
nor does it rule out the possibility for cysteines to be
modified in other ways (i.e. nitrosylation).
Interestingly, Flot1 showed a congruent relationship
with the palmitoylation of Dsg2, in its localisation to
the cell borders in SCC cells (Figure 3(a)). The role of
palmitoylation of Dsg2 in influencing lipid raft
dynamics and exosome release still remains unclear.
Altered protein palmitoylation has been implicated
in several disease states including cancer and
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Table 3. Dsg2-dependent miRNA changes in cells and EVs. RNAseq data for miRNA expression in A431 SCC cells in response to
Dsg2. Complete list of 93 cellular and 19 EV miRNAs modified in response to Dsg2.
Cells
miRNA
hsa-miR-4751
hsa-miR-3614-3p
hsa-miR-155-5p
hsa-miR-489-3p
hsa-miR-1343-3p
hsa-miR-335-3p
hsa-miR-1268b
hsa-miR-941
hsa-miR-1303
hsa-miR-550a-3-5p
hsa-miR-339-5p
hsa-miR-125b-5p
hsa-miR-345-5p
hsa-miR-378a-5p
hsa-miR-222-3p
hsa-miR-455-3p
hsa-miR-3935
hsa-miR-1268a
hsa-miR-3158-3p
hsa-miR-424-3p
hsa-miR-4530
hsa-miR-3908
hsa-miR-30d-5p
hsa-miR-4746-5p
hsa-miR-185-3p
hsa-miR-589-5p
hsa-miR-574-3p
hsa-miR-181a-5p
hsa-miR-614
hsa-miR-4745-5p
hsa-miR-100-5p
hsa-miR-193b-3p
hsa-miR-6822-3p
hsa-miR-1275
hsa-miR-1260b
hsa-miR-181a-2-3p
hsa-miR-218-1-3p
hsa-miR-1249-3p
hsa-miR-210-5p
hsa-miR-423-3p
hsa-miR-125a-3p
hsa-miR-4286
hsa-miR-675-5p
hsa-miR-520g-5p
hsa-miR-483-3p
hsa-miR-937-3p
hsa-miR-221-3p
hsa-miR-17-5p
hsa-miR-548av-5p
hsa-miR-548k
hsa-miR-181d-5p
hsa-miR-4315
hsa-miR-151a-3p
hsa-miR-4443
hsa-miR-224-5p
hsa-miR-130a-3p
hsa-miR-218-5p
hsa-miR-452-5p
hsa-miR-27a-3p
hsa-miR-30b-5p
hsa-miR-26b-5p
hsa-miR-200a-3p
hsa-miR-6718-5p
hsa-miR-455-5p
hsa-miR-16-2-3p
hsa-miR-4283
hsa-miR-141-3p
hsa-miR-30c-5p
hsa-miR-4322

P value
3.4E-02
2.4E-02
1.6E-02
4.7E-02
1.4E-02
2.2E-02
1.7E-02
3.7E-03
4.3E-03
5.4E-02
2.0E-02
3.7E-02
1.5E-03
5.2E-02
2.3E-02
8.7E-03
4.4E-02
3.3E-03
1.6E-02
4.3E-02
2.4E-02
1.9E-02
4.0E-02
2.1E-02
2.1E-02
9.2E-03
3.5E-02
2.9E-02
2.9E-02
3.6E-02
3.7E-02
3.2E-02
4.7E-02
2.2E-02
3.1E-02
1.3E-02
3.3E-05
6.0E-03
4.2E-02
2.2E-02
2.2E-02
5.0E-02
4.0E-02
1.2E-02
1.1E-02
5.4E-03
3.6E-02
5.1E-02
7.8E-03
7.8E-03
2.2E-03
5.1E-03
2.7E-02
2.6E-02
2.8E-02
2.8E-02
4.5E-02
5.2E-02
8.7E-03
5.5E-02
5.7E-03
4.2E-04
2.6E-02
3.1E-02
2.6E-02
2.8E-03
7.3E-03
1.2E-02
3.9E-02

Extracellular vesicles
Fold change
3.494971
3.457813
2.466088
2.396844
2.178318
2.173783
2.08478
2.015638
2.006902
1.988431
1.978894
1.936007
1.921073
1.901527
1.859522
1.854454
1.842817
1.824421
1.778372
1.763534
1.75379
1.738225
1.723596
1.711908
1.70947
1.703309
1.671365
1.631138
1.625194
1.621327
1.600418
1.578689
1.558634
1.546801
1.53002
1.509715
1.496705
1.493437
1.480334
1.457199
1.452636
1.416065
1.398583
1.354219
1.28771
1.24022
1.239406
1.162815
1.157471
1.157471
−1.090434
−1.093118
−1.169172
−1.244754
−1.255403
−1.267563
−1.325368
−1.32573
−1.378141
−1.385742
−1.409554
−1.432015
−1.436837
−1.503326
−1.512259
−1.559243
−1.571711
−1.624972
−1.723357

miRNA
hsa-miR-148a-5p
hsa-miR-1249-3p
hsa-miR-155-5p
hsa-miR-574-3p
hsa-miR-1237-5p
hsa-miR-1296-5p
hsa-miR-4746-5p
hsa-miR-589-5p
hsa-miR-486-5p
hsa-miR-210-3p
hsa-miR-769-5p
hsa-miR-25-3p
hsa-miR-30d-5p
hsa-let-7a-5p
hsa-miR-328-3p
hsa-miR-95-3p
hsa-miR-103a-3p
hsa-miR-181a-2-3p
hsa-miR-146a-5p

P value
2.6E-02
8.0E-04
5.5E-02
2.6E-02
7.7E-03
3.7E-02
4.8E-02
5.1E-02
4.1E-02
5.3E-02
5.4E-02
1.4E-02
3.3E-02
0.0E + 00
2.1E-02
3.7E-02
5.3E-02
1.9E-03
4.5E-02

Fold change
3.160165
3.010493
2.948538
2.394957
2.361985
2.329467
2.265768
2.114036
1.931873
1.905276
1.547565
1.375542
1.301342
1.265757
1.172835
1.132884
−1.10957
−1.60214
−7.72749

(Continued )
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Table 3. (Continued).
Cells
miRNA
hsa-miR-7641
hsa-miR-99a-5p
hsa-miR-4675
hsa-miR-203a-3p
hsa-miR-98-5p
hsa-miR-101-3p
hsa-miR-454-3p
hsa-miR-29c-3p
hsa-miR-10a-3p
hsa-miR-194-5p
hsa-miR-10a-5p
hsa-miR-301b-3p
hsa-miR-19a-3p
hsa-miR-21-5p
hsa-let-7c-5p
hsa-miR-10b-5p
hsa-miR-944
hsa-miR-374a-5p
hsa-miR-4664-5p
hsa-miR-497-5p
hsa-miR-192-5p
hsa-miR-301a-3p
hsa-miR-342-3p
hsa-miR-146a-5p

P value
3.1E-02
2.1E-02
3.7E-05
8.3E-03
8.7E-03
1.5E-02
1.4E-02
4.1E-02
1.1E-02
1.5E-02
2.2E-03
3.7E-02
1.5E-02
4.5E-02
2.9E-02
2.3E-04
1.1E-02
1.1E-05
3.4E-02
2.8E-02
3.0E-02
4.4E-03
3.0E-05
1.0E-03

Extracellular vesicles
Fold change
−1.723383
−1.799487
−1.815564
−1.824814
−1.831834
−1.843259
−1.865915
−1.909977
−1.942635
−1.956922
−1.968513
−2.007348
−2.043948
−2.049397
−2.054183
−2.183278
−2.186209
−2.355238
−2.532697
−2.590796
−2.808976
−2.928572
−4.24184
−13.1954

approaches that target palmitoylated proteins and pal
mitoyl acyltransferases have the potential for therapeu
tic intervention [51]. Given that Dsg2 can promote
activation of mitogenic signalling cascades and enhance
tumorigenesis, palmitoylation may play a role in the
ability of Dsg2 to promote these properties [8,13].
Although the relationship between EV biogenesis and
Dsg2 palmitoylation remains unclear, it is proposed to
be dependent on the ability of Dsg2 to interact with
lipid raft proteins that have both signalling and struc
tural manifestations. In xenograft models, Dsg2 pro
motes larger tumours (Figure 4(a,b)) and the effect was
dramatically reduced with the cells over-expressing
unpalmitoylated Dsg2 (i.e. Dsg2cacs). This was not
due to the rate of cell growth as palmitoylation did
not have an effect on cell proliferation. We previously
showed that palmitoylation-deficient Dsg2 is unstable
and is degraded by lysosomes more rapidly than WT
Dsg2 [20]. However, some palmitoylation-deficient
Dsg2, that is incorporated into desmosomes, remain
relatively stable (Figure 4(c)). To our knowledge, this is
the first demonstration of expression of an unpalmi
toylated protein (Dsg2cacs) in the in vivo setting
(Figure 4(c)).
In skin, sEVs are secreted by a variety of cell types
including epithelial keratinocytes, stromal fibroblast and
immune cells. While it is well known that sEVs contribute
to tumour development and progression, it remains
unclear the source of sEVs or its content that play a
critical role during malignant transformation. While we
cannot rule out the systemic effects on other cells, a single

miRNA

P value

Fold change

dose of sEVs derived from SCC cells over-expressing
Dsg2 is capable of enhancing the tumorigenic potential
of SCC cells in vivo (Figure 4(d)). As the number of
clinical trials using sEVs are increasing each year, there
is an urgent need to better understand their tissue-specific
content to develop more targeted therapeutic treatments.
Paracrine factors associated with sEVs become key
players modulating the TME, including cytokines and
miRNAs and their interplay is crucial for maintaining
homoeostasis. Released during normal response to infec
tion or wound repair, cytokines have the potential to
inhibit cancer development. However, cancer cells have
hijacked this system by expressing receptors that upon
activation, can promote proliferation and survival.
The recent findings that cytokines are encapsulated
or associated with sEVs allow the cell-cell communica
tion systems to intertwine and facilitate cell stimula
tion. The cytokine array analysis here showed only two
proteins (IL-8 and ICAM-1) overlapped between the
conditioned medium (Figure 5(b)) and the sEVs
(Figure 5(c)). This raises the possibility that 8 of the
10 cytokines altered by Dsg2 in the conditioned med
ium are soluble and not associated with sEVs.
Conversely, 10 of the 12 proteins detected in sEVs
may be EV-encapsulated (Figure 5(c)) and thereby
not detected in the conditioned medium (Figure 5
(b)). We propose that in response to Dsg2, ICAM-1
and IL-8 are up-regulated and bound to the surface of
sEVs. ICAM-1 is up-regulated in many cancers includ
ing breast cancer and oral SCCs [52,53]. Furthermore,
a membrane-associated form of ICAM-1 associates
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Figure 7. Dsg2 alters IL-8 and IRAK1 through miR-146a. (A) The expression of 93 total cellular and 19 EV miRNAs altered in response
to Dsg2 detected by RNASeq (signal > 500 and P = 0.05) as reflected by log-normalised intensities. [(B) and (C)] SCC A341 cells were
treated with scrambled control, miR-146a mimic or miR-146a inhibitor for 24 h and total RNA was isolated. RT-qPCR performed for
IL-8 (B) and IRAK1 (C) and expression levels were normalised to GAPDH (N = 9). For IL-8: Untreated, 1.0 ± 0.2; Scramble, 1.4 ± 0.2;
Mimic 0.4 ± 0.3; Inhibitor, 1.7 ± 0.1. For IRAK1: Untreated, 1.0 ± 0.5; Scramble, 1.3 ± 0.9; Mimic 0.35 ± 0.1; Inhibitor 7.1 ± 04.1.

with exosomes and can inhibit leukocytes from binding
to activated endothelial cells [54]. It is not clear from
these results whether this is the full length ICAM-1 or
soluble form of ICAM-1. Likewise, IL-8 is secreted by
oral SCC cells and has been detected on the surface of
exosomes [36,55]. These findings are in congruent with
our results here that Dsg2-mediated up-regulation of
IL-8 is associated with sEVs.
While IL-8 is found predominantly in the soluble
form, we do not believe that this undermines the
importance of our findings concerning IL-8 asso
ciated with sEVs. Here, we have shown that sEVs,
which are already known to be powerful mediators
of cell signalling, can now act as conduits for cyto
kine signalling. The active sorting of IL-8 onto the
surface of vesicles ties IL-8 signalling to the plethora
of potential targets and downstream functions of
EVs. This effect was mediated by purified EV thus
demonstrating that the effect can occur independent

of the presence of soluble IL-8. Association with
sEVs may increase the local concentration of IL-8
as well as protect it from degradation by circulating
proteases.
The mechanism by which Dsg2 activates malignant
transformation and oncogenesis remains to be deter
mined. Here, RNAseq shows dramatic down-regulation
of miR-146a (Figure 7(a)) which targets the interleu
kin-1 receptor-associated kinase 1 (IRAK1) (Figure 7
(c)) [56]. IRAK1 belongs to the serine-threonine kinase
family that is involved in Toll-like receptor and IL-1
signalling activation which promotes gene expression
of IL-6 and IL-8. Thus, down-regulation of miR-146a
as observed here in response to Dsg2, would promote
IL-8 expression and release (Figure 7(b)). IL-8 is a proinflammatory cytokine that plays a critical role in
tumour progression and metastasis and is up-regulated
in many cancers including oral SCCs [44,46]. A corre
lation between expression of Dsg2 and IL-8 was
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Figure 8. Relationship between tumoural Dsg2 and IL-8 and plasma IL-8 with responsiveness to check-point inhibitor treatment. (A)
Gene expression in tumour tissues was determined by RNA seq (NextSeq 500 using 75bp paired-end chemistry at a depth of 50
million reads). Scatter plot analysis is used to assess the association of IL-8 and Dsg2. R2 value is provided to measure goodness-offit. (B) HNSCC patients (N = 28) were stratified according to clinical response: non-responders (red; N = 18) and responders (blue; N
= 10). Plot shows baseline plasma levels of IL-8 analysed by ELISA. Non-responders, 753 ± 223; responders, 151 ± 32. Statistical
significance was assessed using ANOVA (* = P < 0.008).

observed in HNSCC tumours (Figure 8(a)), and in
patients’ blood plasma, we detected varying levels of
IL-8 (Figure 8(b)). Interestingly, patients with higher
basal levels of IL-8 were less responsive to checkpoint
inhibitor treatment (Nivolumab), suggesting that treat
ment with IL-8 or Dsg2 inhibitor to down-regulate IL8 levels may significantly improve the response of
patients to anti-PD-1 inhibitors.
Our data support previously unexplored roles of
Dsg2, establishing this protein as a modulator of

pro-inflammatory cytokines and the early endosomal
pathway, thus impacting sEV release. In summary,
the results obtained from this study elucidate a novel
function of Dsg2 and shed new light on Dsg2’s
ability to influence the tumour microenvironment
via paracrine mechanisms. Through linking cytokine
signalling to EV biology, we hope that future studies
will build on our work and lead to novel therapies
for SCCs, HNSCC and any cancers linked to Dsg2
dysregulation.
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Figure 9. Schematic showing putative mechanism for increased tumorigenesis in SCC cells via Dsg2-dependent miR-146a downregulation. During malignant transformation, up-regulation of Dsg2 promotes sEV release, down-regulation of miR-146a increases in
IL-8 expression and secretion as soluble or sEV-bound form, which contributes to increase in cell proliferation and migration and
tumour growth.
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